Legend Biotech Corp Stock Price, News & Analysis

Legend Biotech (NASDAQ: LEGN) has appointed Carlos Santos as its new Chief Financial Officer, effective immediately. Santos, who brings extensive experience from pharmaceutical and technology sectors, joins from AstraZeneca where he served as CFO for US Oncology. He succeeds Jessie Yeung, who has been interim CFO since January 2025.

In his new role, Santos will oversee Legend's financial operations with a focus on maintaining a strong balance sheet and achieving profitability. The company aims to reach companywide profitability in 2026, driven by the success of their CAR-T cell therapy franchise, CARVYKTI®.

Legend Biotech (NASDAQ: LEGN) reported strong Q2 2025 results, highlighted by CARVYKTI® net trade sales of $439 million, marking the strongest quarterly performance of any CAR-T therapeutic to date. The company announced groundbreaking five-year CARTITUDE-1 study results showing one-third of multiple myeloma patients remaining progression-free.

Financial highlights include $1.0 billion in cash and equivalents, license revenue of $35.3 million, and collaboration revenue of $219.7 million. The company achieved an adjusted net income of $10.1 million, compared to a $2.5 million loss in Q2 2024. Legend Biotech anticipates reaching operating profitability in 2026.

The company has treated over 7,500 clinical and commercial patients to date and presented promising data for new solid tumor therapies LB2102 and LB1908 at ASCO 2025.

Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has scheduled an investor conference call for Monday, August 11, 2025, at 8:00 am ET to discuss their second quarter 2025 financial results. The company's senior leadership will present the quarterly performance overview during the call.

Investors can access the live audio webcast through a provided weblink. Following the call, both the webcast replay and earnings release will be accessible on Legend Biotech's website in the Investor Relations section under Events and Presentations, approximately two hours after the call's conclusion.

Legend Biotech announced groundbreaking 5-year survival data for CARVYKTI in multiple myeloma treatment at ASCO 2025. In the CARTITUDE-1 study, 33% of heavily pretreated relapsed/refractory multiple myeloma patients remained progression-free for 5+ years after a single CARVYKTI infusion. The study showed median overall survival of 60.7 months, with 32 of 97 patients progression-free without additional treatment. CARTITUDE-4 subgroup analyses demonstrated CARVYKTI's superior efficacy versus standard therapies across various patient groups. The company also presented promising early results from Phase 1 studies of LB1908 in gastroesophageal cancers and LB2102 in lung cancers, showcasing potential in solid tumors. Over 6,500 patients have been treated with CARVYKTI to date, marking it as the first CAR T-cell treatment in multiple myeloma to show overall survival benefit versus standard care.

Legend Biotech (NASDAQ: LEGN) announced new data presentations at ASCO, EHA, and ASGCT conferences showcasing developments in their oncology portfolio. CARVYKTI®, their lead CAR-T therapy for multiple myeloma, demonstrated impressive long-term results with patients remaining alive and progression-free for over 5 years after a single infusion in the CARTITUDE-1 study. The company has treated over 6,500 patients with CARVYKTI® to date. Additionally, CARTITUDE-4 study data showed improved survival rates compared to standard care in key subgroups. Legend will also present preliminary Phase 1 results for two pipeline candidates: LB2102 for lung cancers (licensed to Novartis) and LB1908 for gastroesophageal cancers, marking important progress in expanding cell therapy into solid tumors.

Legend Biotech (NASDAQ: LEGN) has announced an upcoming investor event during the 2025 ASCO Annual Meeting in Chicago. The company will host a live webcast on June 1, 2025, at 6:00 p.m. CT, featuring CEO Ying Huang and CMO Mythili Koneru, who will be joined by expert clinicians to discuss updates from the CARTITUDE development program. Investors can access the webcast through a provided weblink or the company's website under Events and Presentations.

Legend Biotech (NASDAQ: LEGN) reported its Q1 2025 financial results, highlighting strong performance of its flagship product CARVYKTI®. The therapy achieved $369 million in net trade sales and has treated over 6,000 patients to date. Key developments include initiating clinical production at the Tech Lane facility in Belgium, receiving positive CHMP opinion for CARVYKTI's label update, and securing TGA approval in Australia. The company maintains a strong financial position with $1.0 billion in cash and equivalents, providing runway into Q2 2026. Q1 financial results showed collaboration revenue of $185.6 million (up from $78.5M YoY), while net loss was $100.9 million. Legend Biotech expects to achieve company-wide profitability by next year, supported by manufacturing expansion and commercial execution.

Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has scheduled an investor conference call to discuss its first quarter 2025 financial results. The call will take place on Tuesday, May 13, 2025, at 8:00 am ET.

Key Details:

• Senior leadership will present the company's Q1 2025 performance
• Investors can access the live audio webcast through a provided weblink
• A replay of the webcast and earnings release will be available
• Post-call materials will be accessible through Legend Biotech's Investor Relations website under Events and Presentations

The materials will be made available approximately two hours after the call concludes.

Legend Biotech (NASDAQ: LEGN) reported strong financial results for Q4 and full year 2024. CARVYKTI® achieved net trade sales of $334 million in Q4 and $963 million for the full year, with over 5,000 patients treated to date.

Key highlights include initiating commercial production at a Novartis facility and securing Spanish reimbursement approval for CARVYKTI® in second-line plus settings. The company reported $1.1 billion in cash and cash equivalents as of December 31, 2024, providing runway into Q2 2026.

Financial results showed significant growth with collaboration revenue reaching $168.0 million in Q4 2024, up from $79.4 million in Q4 2023. License revenue was $18.3 million in Q4 2024. The company reported a net income of $26.3 million ($0.07 per share) in Q4 2024, compared to a net loss of $144.8 million in Q4 2023.